Synapse Biomedical
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7 Rue De La Liberation, Enghien-les-Bain...Website
www.synapsebiomedical.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Synapse Biomedical
Synapse Biomedical specializes in the research, development, and commercialization of innovative neurostimulation products, particularly the NeuRx Diaphragm Pacing System. This technology is designed to prevent and treat Ventilator Induced Diaphragm Dysfunction (VIDD) and reduce reliance on mechanical ventilation for patients with spinal cord injuries and ALS. Their services cater to healthcare professionals and patients, providing solutions that enhance quality of life through minimally invasive procedures. With a commitment to compassionate service, Synapse Biomedical has successfully treated over 2000 patients, offering them a renewed sense of independence.Explore more
Synapse Biomedical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Synapse Biomedical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Synapse Biomedical has new funding data
Click to see if Synapse Biomedical had a recent Job posting/layoffs
Earning: See what the market has to say on Synapse Biomedical recently announced quarterly report
Synapse Biomedical, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Synapse Biomedical launches new products
Congratulate Masked Content for being promoted to Masked Content at Synapse Biomedical
Website visits: Recent activity has been detected on your website
Check out if Synapse Biomedical is spiking on competitors!
Check if Synapse Biomedical has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Synapse Biomedical as Masked Content
Find more new buyers
Compare Similar Companies to Synapse Biomedical
Compare insights from companies similar to Synapse Biomedical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Synapse Biomedical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Synapse Biomedical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Synapse Biomedical.
Synapse Biomedical financials insights
Gather financial insights about Synapse Biomedical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
2021
Debt
$560K
Synapse Biomedical Tech Stack
A closer look at the technologies used by Synapse Biomedical
See more technologies
Synapse Biomedical News & Media
Synapse Biomedical’s Diaphragm Pacing System Gets FDA Premarket Approval
The FDA granted premarket approval of Synapse Biomedical's NeuRx Diaphragm Pacing System for use in patients with spinal cord injuries.Synapse Biomedical Wins New Approval for Diaphragm Pacing System to Free Patients from Ventilators
Ruling will make device more affordable and accessible for those with spinal cord injuries OBERLIN, Ohio, April 5, 2023 /PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®) for use in...FDA Grants Breakthrough Designation to Synapse Biomedical's TransAeris® System
OBERLIN, Ohio, July 21, 2021 /PRNewswire/ -- Synapse Biomedical, Inc®. (www.synapsebiomedical.com) announced today that the FDA has granted Breakthrough Therapy Device designation to TransAeris®, a temporary percutaneous intramuscular diaphragm stimulator designed to aid in weaning from...Diaphragm Pacing can Enhance Recovery and Weaning from Mechanical Ventilation (MV) in Cardiac Surgery
OBERLIN, Ohio, Oct. 1, 2020 /PRNewswire/ -- Synapse Biomedical, Inc®. (www.synapsebiomedical.com) announced today that surgeons at University Hospitals Cleveland Medical Center have improved the prognosis of several cardiac patients after the use of TransAeris DP for the prevention and...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Synapse Biomedical
Sign Up For FreeTo access detailed company insights
Synapse Biomedical specializes in the research, development, and commercialization of innovative neurostimulation products, particularly the NeuRx Diaphragm Pacing System. This technology is designed to prevent and treat Ventilator Induced Diaphragm Dysfunction (VIDD) and reduce reliance on mechanical ventilation for patients with spinal cord injur... Read More
